Teleflex Inc. $(TFX)$, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.